Stanford University
stanford.eduTotal trials
2,115
Active
472
Phase 3
83
Total enrollment
4,917,237
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 181 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ketamine | — | — | 7 | ||||
| Propofol | — | 6 | |||||
| Normal saline | — | — | — | 6 | |||
| Ropivacaine | — | — | — | — | 3 | ||
| Tirzepatide | — | — | — | — | 2 | ||
| Metformin | — | — | — | — | 2 | ||
| Low sodium oxybate | — | — | — | — | — | 1 | |
| Amiodarone | — | — | — | — | — | 1 | |
| Sulfadoxine pyrimethamine + Amodiaquine | — | — | — | — | — | 1 | |
| Dihydroartemisinin Piperaquine | — | — | — | — | — | 1 | |
| Dihydroartemisinin Piperaquine Placebo | — | — | — | — | — | 1 | |
| Sulfadoxine pyrimethamine + Amodiaquine placebo | — | — | — | — | — | 1 | |
| Anti-convulsant medications | — | — | — | — | — | 1 | |
| Anti-depressant medications | — | — | — | — | — | 1 | |
| OnabotulinumtoxinA 100 UNT [Botox] | — | — | — | — | — | 1 | |
| Sodium Chloride 0.9% for Injection, Preservative Free | — | — | — | — | — | 1 | |
| GLP-1A | — | — | — | — | — | 1 | |
| Acetaminophen | — | — | 8 | ||||
| Pioglitazone | — | — | — | 5 | |||
| N-acetylcysteine | — | — | — | — | 3 | ||
| Nebivolol | — | — | — | — | 2 | ||
| Standardized seizure protocol | — | — | — | — | — | 1 | |
| Conventional seizure protocol | — | — | — | — | — | 1 | |
| Cilostazol 100 mg | — | — | — | — | — | 1 | |
| Low-Dose Aspirin Dose: 81 mg & Lansoprazole Dose: 30 mg | — | — | — | — | — | 1 | |
| N acetyl cysteine | — | — | — | — | — | 1 | |
| Tretinoin 0.1% cream | — | — | — | — | — | 1 | |
| Bland cream | — | — | — | — | — | 1 | |
| Amlodipine | — | — | — | — | — | 1 | |
| Dexmedetomidine (IV) 0.5 mcg/kg | — | — | — | — | — | 1 | |
| Ripasudil | — | — | — | — | — | 1 | |
| Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg. | — | — | — | — | — | 1 | |
| Intra-operative single dose (iv) of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg (every 4 hours) or "clindamycin" 150mg(every 6 hours) for 3 days | — | — | — | — | — | 1 | |
| Tizanidine | — | — | — | — | — | 1 | |
| Topical Ripasudil | — | — | — | — | — | 1 | |
| Topical Placebo | — | — | — | — | — | 1 | |
| Panitumumab-IRDye800 | — | — | — | — | — | 3 | |
| Pembrolizumab | — | — | — | — | — | 3 | |
| Panitumumab | — | — | — | — | — | 2 | |
| Rituximab | — | — | — | 9 |
141 more active programs hidden
Next readouts
- 2021-12-14
- 2023-06-20
- 2025-02
- 2025-04-03
- 2025-05
- 2025-05-16
- 2025-06-20
- 2025-08
- 2025-08-15
- 2025-08-15
Top conditions
- Breast Cancer57
- Obesity55
- Depression53
- Pain39
- Autism Spectrum Disorder33
- Anxiety31
- Chronic Pain29
- Influenza26
Frequently asked questions about Stanford University
- How many clinical trials does Stanford University have on ClinicalTrials.gov?
- Stanford University is listed as the lead sponsor on 2,115 clinical trials in ClinicalTrials.gov, 472 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Stanford University's trials are in Phase 3?
- 83 of Stanford University's trials are in Phase 3, spread across 181 active drug programs.
- What therapeutic areas does Stanford University focus on?
- Stanford University's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Obesity, Depression, Pain, Autism Spectrum Disorder.
- When are Stanford University's next clinical trial readouts?
- Stanford University has 10 upcoming primary-completion readouts tracked here; the soonest is “High-Dose Brachytherapy in Treating Patients With Prostate Cancer”, expected around 2021-12-14.